0001213900-22-040285.txt : 20220719 0001213900-22-040285.hdr.sgml : 20220719 20220719160558 ACCESSION NUMBER: 0001213900-22-040285 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220716 FILED AS OF DATE: 20220719 DATE AS OF CHANGE: 20220719 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fry Hannah CENTRAL INDEX KEY: 0001938146 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36694 FILM NUMBER: 221091628 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protara Therapeutics, Inc. CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 204580525 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-844-0337 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: ArTara Therapeutics, Inc. DATE OF NAME CHANGE: 20200110 FORMER COMPANY: FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC DATE OF NAME CHANGE: 20060420 3 1 ownership.xml X0206 3 2022-07-16 0 0001359931 Protara Therapeutics, Inc. TARA 0001938146 Fry Hannah C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 3RD FLOOR NEW YORK NY 10010 0 1 0 0 VP, Controller Common Stock 2600 D Stock Option (right to buy) 24.02 2030-04-30 Common Stock 2600 D Stock Option (right to buy) 26.32 2030-08-06 Common Stock 500 D Stock Option (right to buy) 17.94 2030-10-29 Common Stock 500 D Stock Option (right to buy) 19.82 2031-01-18 Common Stock 3250 D Stock Option (right to buy) 6.95 2031-09-30 Common Stock 2500 D Stock Option (right to buy) 6.90 2032-01-02 Common Stock 5300 D The shares reported are issued pursuant to a restricted stock unit (RSU) award, of which each RSU represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second, and third anniversaries of January 3, 2022. 25% of the shares vest on the one year anniversary of May 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of August 7, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of October 30, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of October 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Exhibit 24.1 - Power of Attorney Mary Grendell, Attorney-in-Fact 2022-07-18 EX-24.1 2 ea163020ex24-1_protarather.htm POWER OF ATTORNEY

Exhibit 24.1 – Power of Attorney

 

POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jesse Shefferman and Mary Grendell, signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

 

(1)execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Protara Therapeutics, Inc. (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules thereunder;

 

(2)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

 

(3)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13 day of July, 2022.

 

/s/ Hannah Fry

Hannah Fry